This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Changes in Pituitary Iron and Volume With Deferasirox

This study has been completed.
Novartis Pharmaceuticals
Information provided by:
Children's Hospital Los Angeles Identifier:
First received: June 17, 2011
Last updated: NA
Last verified: July 2010
History: No changes posted
Despite continuing advances in iron chelation therapy, iron toxicity of endocrine glands, particularly the pituitary gland, remains common in patients with transfusion dependent anemias. We would like to establish accurate population norms of pituitary R2 and volume and understand the progression of pituitary iron in transfused patients on Deferasirox.

Iron Overload

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Changes in Pituitary Iron and Volume With Deferasirox in Transfusional Iron Overload

Resource links provided by NLM:

Further study details as provided by Children's Hospital Los Angeles:

Enrollment: 130
Study Start Date: November 2008
Chronically Transfusion Patients
Patients with transfusion dependent anemia (excluding sickle cell disease), ages 2-25, on Deferasirox chelation therapy, to be monitored over 2 years.
Normal controls, ages 2-25, with no known brain abnormality or endocrine dysfunction.


Ages Eligible for Study:   2 Years to 25 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Transfusion Dependent Anemia

Inclusion Criteria:

  • Currently on chronic transfusion therapy.
  • Duration of chronic transfusion >1 year.
  • Age 2 to 25 years
  • On deferasirox monotherapy for the duration of the study.
  • Informed consent from legal guardian and/or patient.
  • On deferasirox for a minimum of 3 months at start of study.

Exclusion Criteria:

  • Sickle cell disease or sickle-beta zero genotype.
  • Combination of deferasirox and another iron chelator.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01376622

United States, California
Children's Hospital Los Angeles
Los Angeles, California, United States, 90027
Sponsors and Collaborators
Children's Hospital Los Angeles
Novartis Pharmaceuticals
Principal Investigator: John C Wood, MD, PhD Children's Hospital Los Angeles
  More Information

Responsible Party: Dr. John Wood, Children's Hospital Los Angeles Identifier: NCT01376622     History of Changes
Other Study ID Numbers: CICL670AUS29T
CCI-08-00143 ( Other Identifier: Committee on Clinical Investigations )
Study First Received: June 17, 2011
Last Updated: June 17, 2011

Additional relevant MeSH terms:
Iron Overload
Iron Metabolism Disorders
Metabolic Diseases
Iron Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action processed this record on September 21, 2017